BioSpace News Archive

Biotech Bay

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

Eiger BioPharmaceuticals, Inc. today provided the company’s outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.

January 6, 2022
·
4 min read
Business

Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Christine Ann Miller to its Board of Directors, effective immediately.

January 6, 2022
·
5 min read
Genetown

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, outlined key clinical and operational milestones that are expected for the company in 2022.

January 6, 2022
·
6 min read
Job Trends

Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability

Horizon Therapeutics plc announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland.

January 6, 2022
·
4 min read
Drug Development

Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates

Nimbus Therapeutics today announced initiation of a Phase 2b study of the company’s investigational oral allosteric TYK2 inhibitor in patients with active psoriatic arthritis.

January 6, 2022
·
4 min read
Biotech Bay

Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC).

January 6, 2022
·
7 min read
Deals

Stryker announces definitive agreement to acquire Vocera Communications

Stryker (NYSE: SYK) announced today a definitive merger agreement to acquire all of the issued and outstanding shares of common stock of Vocera Communications, Inc.

January 6, 2022
·
8 min read
Business

Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch

Biofidelity, a pioneer in precision cancer diagnostics, has expanded its Scientific Advisory Board to include Lee N. Newcomer, MD.

January 6, 2022
·
4 min read
Biotech Bay

Endpoint Health Presents Published Results from a Retrospective Study of Adult ARDS Patients, Identifying an Innovative Approach to Predicting Clinical Outcomes

Endpoint Health, Inc. today announced that researchers have identified two new, clinically distinct subgroups (subphenotypes) of adults with acute respiratory distress syndrome (ARDS).

January 6, 2022
·
7 min read
Biotech Bay

Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Ambagon Therapeutics today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.

January 6, 2022
·
4 min read